Evidence map›Paper›PMID 36814187›Full record

ArticleBMC infectious diseases2023

COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center.

Natalie L Vawter, Job G Godino, Sydney V Lewis, Adam W Northrup, Jane C Samaniego, Jacqueline Y Poblete, Jesus A Guereca, Sydney P Sharp, Eva Matthews, Noe C Crespo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. COVID‑19 vaccination in liver transplant recipients (Review).Experimental and therapeutic medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Natalie L VawterLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Job G GodinoLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Sydney V LewisLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Adam W NorthrupLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Jane C SamaniegoLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Jacqueline Y PobleteLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Jesus A GuerecaLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Sydney P SharpLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Eva MatthewsLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA.
Noe C CrespoSchool of Public Health, San Diego State University, San Diego, CA, USA.
Pauline G LucateroFamily Health Centers of San Diego, San Diego, CA, USA.
Monica M VidaurrazagaFamily Health Centers of San Diego, San Diego, CA, USA.
Christian B RamersLaura Rodriguez Research Institute, Family Health Centers of San Diego, 1750 5th Ave, San Diego, CA, 92101, USA. christianr@fhcsd.org.
Family Health Centers of San Diego · USSan Diego State University · USHuman Longevity (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonoclonal antibody (mAb) treatment for COVID-19 is associated with improved clinical outcomes. However, there is limited information regarding the impact of treatment on symptoms and the prevalence of post-COVID Conditions (PCC). Understanding of the association between time to mAb infusion and the development of PCC is also limited.

methodsThis longitudinal study was conducted among patients with COVID-19 who received mAb infusions at a Federally Qualified Health Center in San Diego, CA. A series of telephone interviews were conducted at baseline and follow-up (14 days and 28+ days). A comprehensive symptom inventory was completed and physical and mental health status were measured using PROMIS-29 and PHQ-2. Pearson's Chi-squared tests and independent two-sample t-tests were performed to test for association between time to mAb infusion and outcomes at follow-up. A Poisson regression model was used to analyze whether time to mAb infusion predicts risk of developing PCC.

resultsParticipants (N = 411) were 53% female, ranged in age from 16 to 92 years (mean 50), and a majority (56%) were Latino/Hispanic. Cross-sectional findings revealed a high symptom burden at baseline (70% of patients had cough, 50% had fever, and 44% had headache). The prevalence of many symptoms decreased substantially by the final follow-up survey (29% of patients had cough, 3% had fever, and 28% had headache). Longitudinal findings indicated that 10 symptoms decreased in prevalence from baseline to final follow-up, 2 remained the same, and 14 increased. The severity of symptoms and most patient-reported physical and mental health measure scores decreased over time. The prevalence of PCC was 69% when PCC was defined as ≥ 1 symptom at final follow-up. Time to mAb infusion was not significantly associated with any outcome at follow-up. Time to infusion was not associated with PCC status at final follow-up in the crude or adjusted Poisson regression models.

conclusionsThe prevalence of PCC was high among this patient population following COVID-19 mAb treatment. Time to mAb infusion did not predict the development of PCC. Further research in these areas is essential to answer urgent clinical questions about effective treatments of COVID-19.

Indexed as

COVID-19AdolescentAdultAgedAged, 80 and overCoughCross-Sectional StudiesFemaleHeadacheHumansLongitudinal StudiesMaleMiddle AgedPost-Acute COVID-19 SyndromeYoung AdultCOVID-19COVID-19 symptomsMonoclonal antibodiesPost-COVID conditions

Identifiers

PMID36814187
PMCPMC9944776
OpenAlexW4321487569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.